Eliana Merle
Stock Analyst at Barclays
(3.63)
# 903
Out of 5,182 analysts
112
Total ratings
45.98%
Success rate
8.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Equal-Weight | $25 → $48 | $48.70 | -1.44% | 10 | Apr 2, 2026 | |
| INSM Insmed | Maintains: Overweight | $231 → $237 | $135.98 | +74.29% | 2 | Apr 1, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $24 → $41 | $40.95 | +0.12% | 10 | Apr 1, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $95 → $106 | $72.23 | +46.75% | 1 | Mar 26, 2026 | |
| QURE uniQure | Maintains: Equal-Weight | $31 → $25 | $17.90 | +39.66% | 6 | Mar 23, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Overweight | $923 | $744.44 | +23.99% | 1 | Mar 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $80 → $105 | $53.81 | +95.15% | 4 | Mar 4, 2026 | |
| TPG TPG Inc. | Maintains: Overweight | $69 → $56 | $42.93 | +30.44% | 2 | Mar 2, 2026 | |
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.35 | -13.92% | 5 | Feb 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $606 → $607 | $426.01 | +42.48% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59 | $36.92 | +59.80% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $8 | $8.12 | -1.48% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $68 → $119 | $69.22 | +71.92% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $66 | $31.97 | +106.44% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $964 | $520.09 | +85.35% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $5.13 | +250.88% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $226.66 | +50.89% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.45 | +249.21% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $74.52 | +7.35% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $308.51 | +70.82% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $2.80 | +757.14% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $66.59 | -69.97% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $20.98 | -42.80% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $1.86 | +330.11% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $10.29 | +104.08% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $86.68 | -19.24% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $4.25 | -48.24% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $131.67 | -46.08% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $102.06 | +28.36% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $44.11 | -88.66% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $52.95 | -66.01% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $19.29 | +14.05% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.62 | +445.24% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.49 | +10.42% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $28.55 | +369.35% | 3 | Aug 19, 2020 |
Moderna
Apr 2, 2026
Maintains: Equal-Weight
Price Target: $25 → $48
Current: $48.70
Upside: -1.44%
Insmed
Apr 1, 2026
Maintains: Overweight
Price Target: $231 → $237
Current: $135.98
Upside: +74.29%
Apellis Pharmaceuticals
Apr 1, 2026
Maintains: Equal-Weight
Price Target: $24 → $41
Current: $40.95
Upside: +0.12%
Ionis Pharmaceuticals
Mar 26, 2026
Maintains: Overweight
Price Target: $95 → $106
Current: $72.23
Upside: +46.75%
uniQure
Mar 23, 2026
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $17.90
Upside: +39.66%
Regeneron Pharmaceuticals
Mar 6, 2026
Initiates: Overweight
Price Target: $923
Current: $744.44
Upside: +23.99%
BioMarin Pharmaceutical
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $53.81
Upside: +95.15%
TPG Inc.
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $42.93
Upside: +30.44%
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.35
Upside: -13.92%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $426.01
Upside: +42.48%
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $36.92
Upside: +59.80%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $8.12
Upside: -1.48%
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $69.22
Upside: +71.92%
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $31.97
Upside: +106.44%
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $520.09
Upside: +85.35%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $5.13
Upside: +250.88%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $226.66
Upside: +50.89%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $9.45
Upside: +249.21%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $74.52
Upside: +7.35%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $308.51
Upside: +70.82%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $2.80
Upside: +757.14%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $66.59
Upside: -69.97%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $20.98
Upside: -42.80%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $1.86
Upside: +330.11%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $10.29
Upside: +104.08%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $86.68
Upside: -19.24%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $4.25
Upside: -48.24%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $131.67
Upside: -46.08%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $102.06
Upside: +28.36%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $44.11
Upside: -88.66%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $52.95
Upside: -66.01%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $19.29
Upside: +14.05%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.62
Upside: +445.24%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.49
Upside: +10.42%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $28.55
Upside: +369.35%